Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

7.280 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 7.280
Bid (Size) 7.170 (300)
Ask (Size) 11.64 (200)
Prev. Close 7.280
Today's Range 7.280 - 7.280
52wk Range 3.533 - 7.550
Shares Outstanding 72,407,215
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Halper Sadeh LLC is Investigating Whether APLS, CNTA, KZR, EQH are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Shareholder Alert: Ademi LLP investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
From Ademi LLP
Via GlobeNewswire

Performance

YTD
+15.7%
+15.7%
1 Month
+13.2%
+13.2%
3 Month
+18.4%
+18.4%
6 Month
+16.9%
+16.9%
1 Year
+75.4%
+75.4%

More News

Read More
News headline image
KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
From Enodia Therapeutics and Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans ↗
Via Benzinga
News headline image
Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive ↗
Via Stocktwits
Topics Workforce
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
From Kezar Life Sciences
Via Business Wire
News headline image
Kezar Narrows Loss 37 Percent in Q2 ↗
Via The Motley Fool
News headline image
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study ↗
Via Benzinga
News headline image
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate ↗
Via Benzinga
News headline image
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
From Kezar Life Sciences, Inc.
Via Business Wire

Frequently Asked Questions

Is Kezar Life Sciences, Inc. - Common Stock publicly traded?
Yes, Kezar Life Sciences, Inc. - Common Stock is publicly traded.
What exchange does Kezar Life Sciences, Inc. - Common Stock trade on?
Kezar Life Sciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kezar Life Sciences, Inc. - Common Stock?
The ticker symbol for Kezar Life Sciences, Inc. - Common Stock is KZR on the Nasdaq Stock Market
What is the current price of Kezar Life Sciences, Inc. - Common Stock?
The current price of Kezar Life Sciences, Inc. - Common Stock is 7.280
When was Kezar Life Sciences, Inc. - Common Stock last traded?
The last trade of Kezar Life Sciences, Inc. - Common Stock was at 04/21/26 04:00 PM ET
What is the market capitalization of Kezar Life Sciences, Inc. - Common Stock?
The market capitalization of Kezar Life Sciences, Inc. - Common Stock is 527.12M
How many shares of Kezar Life Sciences, Inc. - Common Stock are outstanding?
Kezar Life Sciences, Inc. - Common Stock has 527M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.